← Leaderboards
Keith R Jerome
University Of Washington
$25,774,542
Attributed
$37,867,628
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$58,648,707 · 17
By mechanism
U19$25,189,578 · 3
UM1$24,161,173 · 1
R01$5,651,308 · 3
R21$1,897,631 · 4
R41$607,462 · 1
P30$522,676 · 2
Top collaborators
- Hans-Peter Kiem12 shared
Most similar at University Of Washington
Same institution · by research overlap
- Lawrence A Loeb$30,079,700
- Daniel B Stetson$16,337,119
- Evan E. Eichler$97,393,877
- King Kennard Holmes$42,208,763
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTechnologyMediatingEndonucleaseViralGenomeResearch PersonnelHomingGenesSitePathway InteractionsInnovationBaseSuccessCurative TreatmentsCd4 Positive T LymphocytesVirologyIn VivoNucleaseLaboratoriesMemberMutateVirus DiseasesVirus Replication
Grant awards (56)
A new humanized mouse model to study HBV gene editing$843,440
R01 · FY2025 · AI · contact PI
Meganuclease-mediated gene editing for durable control of HSV-2 infection$303,731
R41 · FY2025 · AI · contact PI
A new humanized mouse model to study HBV gene editing$862,440
R01 · FY2024 · AI · contact PI
Meganuclease-mediated gene editing for durable control of HSV-2 infection$303,731
R41 · FY2024 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$437,702
R01 · FY2022 · AI · contact PI
SWG 5: Curative Therapies for HIV$75,750
P30 · FY2022 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$282,779
R01 · FY2021 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$154,968
R01 · FY2021 · AI · contact PI
SWG 5: Curative Therapies for HIV$72,613
P30 · FY2021 · AI · contact PI
Cell and Gene Therapy for HIV Cure$4,564,019
UM1 · FY2020 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$439,988
R01 · FY2020 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$437,792
R01 · FY2020 · AI · contact PI
Cell and Gene Therapy for HIV Cure$407,345
UM1 · FY2020 · AI · contact PI
SWG 5: Curative Therapies for HIV$78,606
P30 · FY2020 · AI · contact PI
Cell and Gene Therapy for HIV Cure$5,044,836
UM1 · FY2019 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$444,609
R01 · FY2019 · AI · contact PI
CRISPR-assisted provirus tagging in vitro$270,197
R21 · FY2019 · AI · contact PI
SWG 5: Curative Therapies for HIV$87,079
P30 · FY2019 · AI · contact PI
Cell and Gene Therapy for HIV Cure$4,714,991
UM1 · FY2018 · AI · contact PI
Endonuclease-mediated disruption of latent HSV as curative therapy$450,090
R01 · FY2018 · AI · contact PI
CRISPR-assisted provirus tagging in vitro$235,254
R21 · FY2018 · AI · contact PI
SWG 5: Curative Therapies for HIV$68,082
P30 · FY2018 · AI · contact PI
Cell and Gene Therapy for HIV Cure$4,714,991
UM1 · FY2017 · AI · contact PI
In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis$220,000
R21 · FY2017 · AI · contact PI
2017 Conference on Cell and Gene Therapy for HIV CURE$25,000
R13 · FY2017 · AI · contact PI
Scientific Working Groups$5
P30 · FY2017 · AI · contact PI
Cell and Gene Therapy for HIV Cure$4,714,991
UM1 · FY2016 · AI · contact PI
In vivo inactivation of latent HSV by endonuclease-mediated mutagenesis$264,000
R21 · FY2016 · AI · contact PI
Anti-HBV therapeutics based on rare-cutting targeted endonucleases$228,715
R21 · FY2016 · AI · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,371,340
U19 · FY2015 · AI · contact PI
Targeted Disruption of Integrated SHIV by Engineered Homing Endonucleases$620,456
U19 · FY2015 · AI · contact PI
Administrative Core$318,291
U19 · FY2015 · AI · contact PI
Anti-HBV therapeutics based on rare-cutting targeted endonucleases$203,715
R21 · FY2015 · AI · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,068,789
U19 · FY2014 · AI · contact PI
Targeted Disruption of Integrated SHIV by Engineered Homing Endonucleases$628,732
U19 · FY2014 · AI · contact PI
Administrative Core$334,002
U19 · FY2014 · AI · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,375,129
U19 · FY2013 · AI · contact PI
Targeted Disruption of Integrated SHIV by Engineered Homing Endonucleases$590,756
U19 · FY2013 · AI · contact PI
Administrative Core$220,664
U19 · FY2013 · AI · contact PI
Scientific Working Groups$140,541
P30 · FY2013 · AI · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,033,771
U19 · FY2012 · AI · contact PI
Targeted Disruption of Integrated SHIV by Engineered Homing Endonucleases$578,278
U19 · FY2012 · AI · contact PI
Administrative Core$286,052
U19 · FY2012 · AI · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$3,932,050
U19 · FY2011 · AI · contact PI
Targeted Disruption of Integrated SHIV by Engineered Homing Endonucleases$586,798
U19 · FY2011 · AI · contact PI
Administrative Core$244,470
U19 · FY2011 · AI · contact PI
Mechanisms of Inactivation of T Cells by HSV$387,077
R56 · FY2006 · AI · contact PI
Inhibition of CTL killing by HSV$259,500
R01 · FY2005 · AI
Inactivation of CTL by HSV-infected cells$216,250
R21 · FY2005 · AI
Inhibition of CTL killing by HSV$259,500
R01 · FY2004 · AI
Inactivation of CTL by HSV-infected cells$259,500
R21 · FY2004 · AI
Inhibition of CTL killing by HSV$259,500
R01 · FY2003 · AI
Inhibition of CTL killing by HSV$259,500
R01 · FY2002 · AI
Inhibition of CTL killing by HSV$259,500
R01 · FY2001 · AI
HERPES SIMPLEX VIRUS INHIBITION OF CTL INDUCED APOPTOSIS$117,969
K08 · FY2001 · AI
HERPES SIMPLEX VIRUS INHIBITION OF CTL INDUCED APOPTOSIS$88,833
K08 · FY2000 · AI